Full-Time

ML/AI Operations Architect

Evinova

Posted on 6/25/2025

Deadline 7/8/25
AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

Compensation Overview

$167.8k - $251.7k/yr

+ Short-term incentive bonus + Equity-based long-term incentive program

Senior

Gaithersburg, MD, USA

Hybrid

Employees are required to work in the office 3 days a week.

Category
Applied Machine Learning
AI Research
AI & Machine Learning
Required Skills
Kubernetes
Airflow
NoSQL
SQL
Machine Learning
TypeScript
AWS
Requirements
  • HS Diploma and 5 years of experience in Engineering/IT solutions OR BA/BS
  • Minimum of 5 years in cloud infrastructure design and management roles.
  • Deep understanding of the Data Science Lifecycle (DSLC) and the ability to shepherd data science projects from inception to production within the platform architecture.
  • Expert in Typescript, AWS CDK, Projen, and Argo CD and other Cloud Infrastructure CI/CD Tools
  • Extensive experience in managing Kubernetes clusters for ML workflows.
  • Solid understanding of foundation models and their applications in ML/AI solutions.
  • Strong background in AWS DevOps practices and cloud architecture.
  • Deep knowledge of AWS services (Bedrock, Sagemaker, EC2, S3, RDS, Lambda, etc) and hands-on design and implementation cloud systems (microservices architecture, API design, and database management (SQL/NoSQL))
  • Experience with monitoring and optimizing cloud infrastructure for scalability and cost-efficiency.
  • Ability to collaborate effectively with engineering, design, product, science and security teams.
  • Strong written and verbal communication skills for reporting and documentation.
  • Demonstrated ability to manage large-scale, complex projects across an organization.
  • Proven experience in conducting performance and cost analyses of AWS infrastructure and ML/AI models.
Responsibilities
  • Lead by example in creating high-performance, mission-focused and interdisciplinary teams/culture founded on trust, mutual respect, growth mentalities, and an obsession for building extraordinary products with extraordinary people.
  • Drive the creation of proactive capability and process enhancements that ensures enduring value creation and analytic compounding interest.
  • Design and implement resilient cloud ML/AI operational capabilities to improve our system Abilities (Learnability, Flexibility, Extendibility, Interoperability, Scalability).
  • Drive precision and systemic cost efficiency, optimized system performance, and risk mitigation with a data-driven strategy, comprehensive analytics, and predictive capabilities at the tree-and-forest level of our ML/AI systems, workloads and processes.
  • Architect and implement scalable AWS ML/AI cloud infrastructure in a multi-tenant SaaS environment.
  • Establish governance frameworks for ML/AI infrastructure management and ensure compliance with industry standard processes.
  • Ensure principled and methodical validation pathways and a Well Architected Framework for Embryonic Research (WAFER) similar to and building on AWS’s Well Architected Framework (WAF) for all early stage product and operational GenAI PoC’s across the organization.
  • Oversee ML/AI related Kubernetes (k8s) cluster management and provide guidance on alternative ML/AI workflow orchestration options such as Argo vs Kubeflow, and ML/AI data pipeline creation, management and governance with tools like Airflow.
  • Employ AWS CDK (TypeScript), Projen, and Argo CD to automate infrastructure deployment and management.
  • Help set the strategy and manage the tactical balance between framework and platform experimentation and democratization with standardization and centralized management and governance.
  • Conduct cost-benefit analyses and formal processes for selection and utilization of foundation models, evaluating their architectures, performance, and costs.
  • Work with multiple teams to ensure that the platform meets organizational needs and scales effectively.

AstraZeneca develops and sells prescription medicines, focusing on three main areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Their products are created through extensive research and development, followed by clinical trials and regulatory approvals. AstraZeneca stands out from competitors by fostering collaboration through its Open Innovation program and the A.Catalyst Network, which connects health innovation hubs worldwide. The company's goal is to advance healthcare by providing effective treatments for serious diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's AI partnership with Sheffield enhances protein folding and drug discovery.
  • The expansion in Bangalore creates 400 jobs, boosting AstraZeneca's global operations.
  • Strategic stake in Niox Group offers collaboration opportunities in the pharmaceutical sector.

What critics are saying

  • Expansion in Bangalore may face challenges from local regulatory changes.
  • Stake in Niox Group exposes AstraZeneca to financial risks if Niox underperforms.
  • CSPC collaboration may be affected by geopolitical tensions or trade restrictions.

What makes AstraZeneca unique

  • AstraZeneca focuses on three main therapy areas: Oncology, Cardiovascular, and Respiratory.
  • The company invests heavily in R&D to create innovative prescription medicines.
  • AstraZeneca's A.Catalyst Network fosters global collaboration and innovation in healthcare.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

HRKatha
Jun 27th, 2025
AstraZeneca creates 400 jobs, expands its global hub in Bangalore

AstraZeneca creates 400 jobs, expands its global hub in Bangalore.

Devdiscourse
Jun 18th, 2025
AstraZeneca's Stake in Niox Group: A Strategic Partnership | Headlines

AstraZeneca PLC has acquired a significant stake of 15.86% in Niox Group PLC, according to a recent company filing. This move signals strategic collaboration opportunities between the two companies, potentially aligning their interests in the pharmaceutical industry and expanding their influence in the sector.

InfBusiness
Jun 17th, 2025
Scientists present AI solution for protein folding

Scientists from the University of Sheffield, in partnership with AstraZeneca, have developed an artificial intelligence system called MapDiff, which allows for more efficient creation of proteins with a giventhree-dimensional structure and biological functions.

Cision
Jun 13th, 2025
Astrazeneca Enters Into Collaboration With Cspc

AstraZeneca enters into collaboration with CSPC

Cision
Jun 6th, 2025
Fixed-Duration Calquence Approved In Eu For 1L Cll

Fixed-duration Calquence approved in EU for 1L CLL

INACTIVE